Finance

Lists
EVMN:NYSE
Evommune Inc
5,77 US$
-1,87%
(-0,11) 1D
5,77 US$
0,00% (0,00)
After hours
Closed: 14 ოქტ, 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVMN...
Open
5,79 US$
High
5,96 US$
Low
5,64 US$
Mkt. cap
209,41 მლნ.
Avg. vol.
903,54 ათ.
Volume
0,00
52-wk high
33,20 US$
52-wk low
5,64 US$
EPS
-2,89 US$
Shares outstanding
36,29 მლნ.
No. of employees
48
Open
5,79 US$
High
5,96 US$
Low
5,64 US$
Mkt. cap
209,41 მლნ.
Avg. vol.
903,54 ათ.
Volume
0,00
52-wk high
33,20 US$
52-wk low
5,64 US$
EPS
-2,89 US$
Shares outstanding
36,29 მლნ.
No. of employees
48
News stories
From web sources and news partners
About Evommune Inc
CEO-
Employees48
Founded2020
Headquartersპალო-ალტო, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 13 analysts giving stock ratings to EVMN in the past 3 months
Strong buy
Buy
10
Hold
3
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for EVMN in the last 3 months.
Highest
Current 5,77 US$
30,00 US$ (+419,93%)
Average
22,40 US$ (+288,21%)
Lowest
8,00 US$ (+38,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alice Nettleton
UBS
Hold
Initiated
8,00 US$
+38,6%
10/12/2026
Unknown Analyst
UBS
Hold
Initiated
8,00 US$
+38,6%
10/11/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
10/05/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
-
-
09/17/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
23,00 US$
+298,6%
09/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
30,00 US$
+419,9%
09/09/2026
Serge Belanger
Needham
Buy
Maintained
28,00 US$
+385,3%
09/09/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
22,00 US$
+281,3%
09/10/2026
Martin Auster
Raymond James
Buy
Maintained
18,00 US$
+212%
09/09/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
26,00 US$
+350,6%
09/09/2026
Brian Abrahams
RBC Capital
Buy
Maintained
21,00 US$
+264%
09/08/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
09/09/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
22,00 US$
+281,3%
08/10/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
26,00 US$
+350,6%
08/10/2026
Last report
6 აგვ. 2026
Fiscal period
Q2 2026
-0,89 US$ / -0,67 US$
-32,84%miss
Revenue / Est. (USD)
- / 1,14 მლნ.
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
10,00 მლნ.
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19,64 მლნ.
20,40 მლნ.
17,32 მლნ.
26,41 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,69 მლნ.
9,31 მლნ.
6,64 მლნ.
8,48 მლნ.
Operating expense
23,33 მლნ.
29,72 მლნ.
23,95 მლნ.
34,90 მლნ.
Total operating expenses
23,33 მლნ.
29,72 მლნ.
23,95 მლნ.
34,90 მლნ.
Operating income
-13,33 მლნ.
-29,72 მლნ.
-23,95 მლნ.
-34,90 მლნ.
Other non operating income
-9,00 ათ.
-
-4,00 ათ.
-2,00 ათ.
EBT including unusual items
-12,48 მლნ.
-28,27 მლნ.
-21,67 მლნ.
-32,25 მლნ.
EBT excluding unusual items
-12,48 მლნ.
-28,27 მლნ.
-21,67 მლნ.
-32,25 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,48 მლნ.
-28,27 მლნ.
-21,67 მლნ.
-32,25 მლნ.
Net profit margin
-124,75%
-
-
-
Earnings per share
-8,07
-1,43
-0,64
-0,89
Interest and investment income
862,00 ათ.
1,44 მლნ.
2,28 მლნ.
2,65 მლნ.
Interest expense
-
-
-
-
Net interest expenses
862,00 ათ.
1,44 მლნ.
2,28 მლნ.
2,65 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,02 მლნ.
-29,39 მლნ.
-23,60 მლნ.
-34,34 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები